# Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)

> **NCT01881230** · PHASE2,PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 191 (actual)

## Conditions studied

- Breast Tumor
- Breast Cancer
- Cancer of the Breast
- Estrogen Receptor- Negative Breast Cancer
- HER2- Negative Breast Cancer
- Progesterone Receptor- Negative Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer
- Triple-negative Breast Cancer
- Triple-negative Metastatic Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** nab-Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01881230
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-26
- **Primary completion:** 2016-10-28
- **Final completion:** 2016-10-28
- **Target enrollment:** 191 (ACTUAL)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01881230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01881230, "Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01881230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*